

Problematic References in 10.1371/journal.pone.0347213

A recent investigation by the 5GH Team identified ten problematic references in article [1], specifically references 2, 3, 6, 7, 8, 18, 20, 26, 53, and 56.

By cross-referencing the cited works using journal names, volume numbers, issue numbers, and page/article numbers, the Team found that seven references (6, 7, 18, 20, 26, 53, and 56) do not exist, while the remaining three (2, 3, and 8) have titles and authors different from those listed in the article.

discussions with colleagues at Shanghai Jiao Tong University and Mukhtar Auzov South Kazakhstan State University, Kazakhstan.

References

1. Inci J, Kaplan O. Escherichia coli as a versatile cell factory: advances and challenges in recombinant protein production. *Protein Expr Purif*. 2024;219:106463. PMID: 38479568
[View Article](#) • [PubMed](#) • [Google Scholar](#)
2. Singh PK, Sharma V, Puri PB. Bacterial toxins in cancer therapy: current status and future directions. *Biochim Biophys Acta Rev Cancer*. 2022;1877:188747.
[View Article](#) • [Google Scholar](#)
3. Zhang Y, Zhang J, Wang S. Targeted toxin therapy for hematological malignancies: recent advances and clinical perspectives. *J Hematol Oncol*. 2023;16:45.
[View Article](#) • [Google Scholar](#)
4. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. *Nat Rev Drug Discov*. 2021;20(11):817–38. PMID: 34433919
[View Article](#) • [PubMed](#) • [Google Scholar](#)
5. Seyour EJ, Bockowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. *Nat Rev Clin Oncol*. 2024;21(7):489–500. PMID: 38769500
[View Article](#) • [PubMed](#) • [Google Scholar](#)
6. Liu S, Zhang J, Wang X. Structural insights into bacterial exotoxins: implications for

discussions with colleagues at Shanghai Jiao Tong University and Mukhtar Auzov South Kazakhstan State University, Kazakhstan.

References

1. Inci J, Kaplan O. Escherichia coli as a versatile cell factory: advances and challenges in recombinant protein production. *Protein Expr Purif*. 2024;219:106463. PMID: 38479568
[View Article](#) • [PubMed](#) • [Google Scholar](#)
2. Singh PK, Sharma V, Puri PB. Bacterial toxins in cancer therapy: current status and future directions. *Biochim Biophys Acta Rev Cancer*. 2022;1877:188747.
[View Article](#) • [Google Scholar](#)
3. Zhang Y, Zhang J, Wang S. Targeted toxin therapy for hematological malignancies: recent advances and clinical perspectives. *J Hematol Oncol*. 2023;16:45.
[View Article](#) • [Google Scholar](#)
4. Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. *Nat Rev Drug Discov*. 2021;20(11):817–38. PMID: 34433919
[View Article](#) • [PubMed](#) • [Google Scholar](#)
5. Seyour EJ, Bockowski D, Mitchell DA, Nair SK. Cancer mRNA vaccines: clinical advances and future opportunities. *Nat Rev Clin Oncol*. 2024;21(7):489–500. PMID: 38769500
[View Article](#) • [PubMed](#) • [Google Scholar](#)
6. Liu S, Zhang J, Wang X. Structural insights into bacterial exotoxins: implications for

Access through your organisation Purchase PDF Patient Access

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Volume 1877, Issue 6, July 2022, 188747

Review
HOXA1, a breast cancer oncogene
Mogali Belpaire^{1,2}, Arnaud Tominiou^{1,2}, Dirk Geerts^{1,2,3}, & René Reszohazy^{1,2}

Show more

+ Add to Mendeley Share Cite

<https://doi.org/10.1016/j.bbr.2022.188747> Get rights and content

Abstract

Home > Journal of Immunology & Oncology > Article

The Notch signaling pathway: a potential target for cancer immunotherapy
Review | Open access | Published: 02 May 2023
Volume 16, article number 45, (2023) | [View this article](#)

Download PDF Search article

6. Liu S, Zhang J, Wang X. Structural insights into bacterial exotoxins: implications for therapeutic design. *Front Microbiol*. 2022;13:845312. [View Article](#) • [Google Scholar](#)

7. Kheirallah DA, Al-Hamad A, Al-Hussaini M. Bacterial toxins as anticancer agents: current status and future perspective. *Toxins*. 2023;15:530. [View Article](#) • [Google Scholar](#)

8. Wang X, Li Z, Zhang Y. Challenges in recombinant expression of disulfide-rich proteins in *Escherichia coli*. *Microb Cell Fact*. 2021;20:125. [View Article](#) • [Google Scholar](#)

9. Chen X, Zero J, Shen W-C. Fusion protein linkers: property, design and functionality. *Adv Drug Deliv Rev*. 2013;55(10):1357-69. pmid:23026637 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

10. Gajjar A, Ruddock LW. Complementary determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv. *PLoS One*. 2017;12(12):e0189964. pmid:29253024 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

11. Walsh G. Biopharmaceutical benchmarks 2018. *Nat Biotechnol*. 2018;36:1136-45. [View Article](#) • [Google Scholar](#)

12. Rosano GL, Morales ES, Ceccarelli EA. New tools for recombinant protein production in *Escherichia coli*: A 5-year update. *Protein Sci*. 2019;28(8):1412-22. pmid:31219641

5GH Foundation

Not Found

6. Liu S, Zhang J, Wang X. Structural insights into bacterial exotoxins: implications for therapeutic design. *Front Microbiol*. 2022;13:845312. [View Article](#) • [Google Scholar](#)

7. Kheirallah DA, Al-Hamad A, Al-Hussaini M. Bacterial toxins as anticancer agents: current status and future perspectives. *Toxins*. 2023;15:530. [View Article](#) • [Google Scholar](#)

8. Wang X, Li Z, Zhang Y. Challenges in recombinant expression of disulfide-rich proteins in *Escherichia coli*. *Microb Cell Fact*. 2021;20:125. [View Article](#) • [Google Scholar](#)

9. Chen X, Zero J, Shen W-C. Fusion protein linkers: property, design and functionality. *Adv Drug Deliv Rev*. 2013;55(10):1357-69. pmid:23026637 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

10. Gajjar A, Ruddock LW. Complementary determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv. *PLoS One*. 2017;12(12):e0189964. pmid:29253024 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

11. Walsh G. Biopharmaceutical benchmarks 2018. *Nat Biotechnol*. 2018;36:1136-45. [View Article](#) • [Google Scholar](#)

12. Rosano GL, Morales ES, Ceccarelli EA. New tools for recombinant protein production in *Escherichia coli*: A 5-year update. *Protein Sci*. 2019;28(8):1412-22. pmid:31219641

5GH Foundation

Home > Microbial Cell Factories > Article

Integration of enzyme constraints in a genome-scale metabolic model of *Aspergillus niger* improves phenotype predictions

Research | Open access | Published 30 June 2021

Volume 20, article number 125, (2021) [Cite this article](#)

[Download PDF](#) [Save article](#)

17. Hsu C, Nisonoff H, Fangiang C, Lutzgarten J. Learning protein fitness models from evolutionary and assay-labeled data. *Nat Biotechnol*. 2022;40(7):1114-22. pmid:35036977 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

18. Steward LE, Collins CS, Gilmore MA, Carlson JE, Ross JA, Blonder J, et al. A cell-free assay for *Pseudomonas* exoenzyme A activity identifies a novel inhibitor. *Nat Biotechnol*. 1997;15:355-60. [View Article](#) • [Google Scholar](#)

19. Li Z, Kessler W, van den Heuvel J, Rinas U. Simple defined autoinduction medium for high-level recombinant protein production using T7-based *Escherichia coli* expression systems. *Appl Microbiol Biotechnol*. 2011;91(6):1203-13. pmid:21698378 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

20. Wang Y, Li Y, Ma Z, Yang W, Ai C. Mechanism of action of the *Pseudomonas aeruginosa* type III secretion system Iip protein, PcrV, in bacterial pathogenesis. *Front Microbiol*. 2020;11:570099. [View Article](#) • [Google Scholar](#)

21. Jia B, Jeon CO. High-throughput recombinant protein expression in *Escherichia coli*: current status and future perspectives. *Open Biol*. 2016;6(8):160196. pmid:27581654 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

22. de Marco A, Dwerfing E, Mogh A, Tomoyasu T, Bulkaa B. Chaperone-based procedure to increase yields of soluble recombinant proteins produced in *E. coli*. *BMC Biotechnol*. 2007;7:32. pmid:17565681 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

5GH Foundation

nature biotechnology

Explore content About the journal Publish with us Subscribe

nature > nature biotechnology > research article > article

Research Article | Published: 01 April 1997

A glucosensing polymer

Guohua Chen, Zhibin Guan, Cheng-Jiem Chen, Lifen Fu, Vidyanandhan Sundaresan & Frances H. Arnold

Nature Biotechnology 15, 354-357 (1997) [Cite this article](#)

1954 Accesses | 117 Citations | Altmetric Metrics

17. Hsu C, Nisonoff H, Fangiang C, Lutzgarten J. Learning protein fitness models from evolutionary and assay-labeled data. *Nat Biotechnol*. 2022;40(7):1114-22. pmid:35036977 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

18. Steward LE, Collins CS, Gilmore MA, Carlson JE, Ross JA, Blonder J, et al. A cell-free assay for *Pseudomonas* exoenzyme A activity identifies a novel inhibitor. *Nat Biotechnol*. 1997;15:355-60. [View Article](#) • [Google Scholar](#)

19. Li Z, Kessler W, van den Heuvel J, Rinas U. Simple defined autoinduction medium for high-level recombinant protein production using T7-based *Escherichia coli* expression systems. *Appl Microbiol Biotechnol*. 2011;91(6):1203-13. pmid:21698378 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

20. Wang Y, Li Y, Ma Z, Yang W, Ai C. Mechanism of action of the *Pseudomonas aeruginosa* type III secretion system Iip protein, PcrV, in bacterial pathogenesis. *Front Microbiol*. 2020;11:570099. [View Article](#) • [Google Scholar](#)

21. Jia B, Jeon CO. High-throughput recombinant protein expression in *Escherichia coli*: current status and future perspectives. *Open Biol*. 2016;6(8):160196. pmid:27581654 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

22. de Marco A, Dwerfing E, Mogh A, Tomoyasu T, Bulkaa B. Chaperone-based procedure to increase yields of soluble recombinant proteins produced in *E. coli*. *BMC Biotechnol*. 2007;7:32. pmid:17565681 [View Article](#) • [PubMed\(NCBI\)](#) • [Google Scholar](#)

5GH Foundation

Not Found

spectrometry. *Mol Cell Proteomics*. 2015;14(12):2344-45. PMID: 26080480
[View Article](#) • [PubMed](#) • [Google Scholar](#)

26. Rahimi SM, Zhai JA. Recent advances in E. coli based therapeutic protein expression systems. *Biochem Biophys Res Commun*. 2024;574:1-12.
[View Article](#) • [Google Scholar](#)

27. Gutierrez JM, Lewis NE. Optimizing eukaryotic cell hosts for protein production through systems biotechnology and genome-scale modeling. *Biotechnol J*. 2015;10(7):939-49. PMID: 26095271
[View Article](#) • [PubMed](#) • [Google Scholar](#)

28. Chen T, Questrin C, XGBBoost: A scalable tree boosting system. In: *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*. 2018. pp. 785-94.
[View Article](#) • [Google Scholar](#)

29. Lundberg SM, Erion G, Chen H, DeGrave A, Pruthi JM, Nair B, et al. From local explanations to global understanding with explainable AI for trees. *Nat Mach Intell*. 2020;2(1):56-67. PMID: 32507472
[View Article](#) • [PubMed](#) • [Google Scholar](#)

30. Lundberg SM, Lee SI. A unified approach to interpreting model predictions. *Adv Neural Inf Process Syst*. 2017;30:4765-74.
[View Article](#) • [Google Scholar](#)

31. Hon J, Marouak M, Martinek T, Kurka A, Zondulka J, Bednar D, et al. SoluProt: prediction of soluble protein expression in *Escherichia coli*. *Bioinformatics*.

32. Robinson PJ, Butler NJ. Mechanisms of disulfide bond formation in nascent polypeptides entering the secretory pathway. *Cells*. 2020;9(9):1994. PMID: 32872499
[View Article](#) • [PubMed](#) • [Google Scholar](#)


33. Frigo MJ, Hendershot LM. Disulfide bonds in protein folding and stability. *Methods Mol Biol*. 2011;752:1-15.
[View Article](#) • [Google Scholar](#)

34. Alured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of *Pseudomonas aeruginosa* at 3.0-Ångstrom resolution. *Proc Natl Acad Sci U S A*. 1986;83(5):1320-4. PMID: 3006045
[View Article](#) • [PubMed](#) • [Google Scholar](#)

35. Wedekind JE, Trams CB, Drydenlock M, Koehn P, Raschke TM, McKee M, et al. Refined crystallographic structure of *Pseudomonas aeruginosa* exotoxin A and its implications for the molecular mechanism of toxicity. *J Mol Biol*. 2001;314(4):823-37. PMID: 11734000
[View Article](#) • [PubMed](#) • [Google Scholar](#)

36. Wozniak DJ, Hou LY, Calloway DR. His-426 of the *Pseudomonas aeruginosa* exotoxin A is required for ADP-ribosyltransferase activity. *J Bacteriol*. 1988;170:1912-4.
[View Article](#) • [Google Scholar](#)

37. de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in *Escherichia coli*. *Microb Cell Fact*. 2009;8:26. PMID: 19442264
[View Article](#) • [PubMed](#) • [Google Scholar](#)



Not Found

[1] 10.1371/journal.pone.0347213

This article is licensed to the 5GH Foundation under a CC BY-NC-ND 4.0 International License